Effectiveness for the shorting of hemostatic time using RDI on bleeding by biopsy forceps

Effectiveness for the shorting of hemostatic time using RDI on bleeding by biopsy forcep - RDI-hara study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000046671

Enrollment

Registered

2022-01-19

Start date

2022-01-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ulcerlative colitis

Interventions

RDIInterventions: RDI Control: WLI

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. age:20-80year old, male or female, remission of ulcerlative colitis 2. taking 5-ASA 3. blood examination:hemoglobin more than 8.0g/dL and Platet more than 100000/mm3 4. informed consent

Exclusion criteria

Exclusion criteria: 1. Not remission phase of ulcerlative colitis 2. performed endoscopic hemostasis due to no spontaneous hemostasis 3. takign biopsy from several locations of colon 4. history of taking steroid and/or immunosuppresion medicine and/or biopharmarcy and/or G-CAP 5. no cessation of antithrombotic drugs 6. hemodialysis 7. no take an informed consent

Design outcomes

Primary

Measure	Time frame
shorting of hemostatic time using RDI during colonoscopy	—

Countries

Japan

Contacts

Public Contactkenzo hara

Toho University Omori Medical Center Division of Gastroenterology and hepatology

kenzou.hara@med.toho-u.ac.jp03-3762-4151

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026